NEW YORK — Sustained-release drug delivery for glaucoma treatment offers a way to reduce IOP without relying on surgery or drops and gives physicians a way to customize treatment plans for individual patients, according to a speaker here.
“It really gives us the ability to further customize our treatment plans for our patients,” Sarah H. Van Tassel, MD, said during a discussion about first-line treatment in newly diagnosed patients with glaucoma at OSN New York. “What we can offer our patients in 2021 is a customized treatment plan.”
Sustained-release glaucoma